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Problem: To study the mechanisms of placenta function and the role of extracellular 
vesicles (EVs) in pregnancy, it is necessary to develop an ex vivo system that retains 
placental cytoarchitecture and the primary metabolic aspects, in particular the re-
lease of EVs and soluble factors. Here, we developed such a system and investigated 
the pattern of secretion of cytokines, growth factors, and extracellular vesicles by 
placental villous and amnion tissues ex vivo.
Methods of Study: Placental villous and amnion explants were cultured for 2 weeks 
at the air/liquid interface and their morphology and the released cytokines and EVs 
were analyzed. Cytokines were analyzed with multiplexed bead assays, and individ-
ual EVs were analyzed with recently developed techniques that involved EV capture 
with magnetic nanoparticles coupled to anti- EV antibodies and flow cytometry.
Results: Ex vivo tissues (i) remained viable and preserved their cytoarchitecture; (ii) main-
tained secretion of cytokines and growth factors; (iii) released EVs of syncytiotropho-
blast and amnion epithelial cell origins that contain cytokines and growth factors.
Conclusion:	A	system	of	ex	vivo	placental	villous	and	amnion	tissues	can	be	used	as	
an adequate model to study placenta metabolic activity in normal and complicated 
pregnancies, in particular to characterize EVs by their surface markers and by encap-
sulated proteins. Establishment and benchmarking the placenta ex vivo system may 
provide new insight in the functional status of this organ in various placental disor-
ders, particularly regarding the release of EVs and cytokines. Such EVs may have a 
prognostic value for pregnancy complications.
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1  | INTRODUC TION
The placenta plays a critical role in fetal growth and develop-
ment and orchestrates major maternal adaptations of pregnancy 
such as carbohydrate intolerance1-5 and immune adaptations.6-30 
Placental dysfunction has been implicated in major complications 
of pregnancy such as preeclampsia,31-56 fetal growth restric-
tion,57-72 fetal death,73-80 and preterm labor.81-90 The placenta 
has also been considered as the center of the chronic disease 
universe.91,92
The study of human placentae in vivo is challenging and has 
significant	 restrictions.	 Animal	models	 have	 been	 useful,	 although	
there are fundamental differences in placentation among mam-
mals.93-97 Many studies of human placenta utilize isolated primary 
cells or placenta- derived cell lines.98-101 While major discoveries have 
emerged from such studies,102-104 isolated cells do not adequately 
recapitulate important aspects of tissue function related to cell- 
cell communications in vivo. This is the rationale to develop three- 
dimensional models that maintain the cellular relationships ex vivo. 
Such three- dimensional models have proven to be of major value in 
investigating cancer development,105-109 viral pathogenesis,110-113 
and testing anticancer114 and antiviral compounds115 under con-
trolled laboratory conditions.
It is now increasingly apparent that the maternal- fetal dia-
logue is more complex than previously recognized.116-119 In ad-
dition to many soluble factors, such as hormones and cytokines 
implicated in this communication, it is now recognized that ex-
tracellular vesicles (EVs) can also mediate crosstalk between the 
feto- placental unit and the mother.120-131 Extracellular vesicles 
carry	 lipids,	 proteins,	 and	 miRNA	 that	 can	 convey	 information	
about the status of the fetus and placenta.132-134 Moreover, EVs 
carry immune mediators (eg, cytokines) that facilitate cell- to- cell 
communication, which are present on both the surface and inside 
the microvesicles.135-145
To study the mechanisms of placental function and the role of 
EVs in pregnancy, it is necessary to develop an ex vivo system that 
retains placental cytoarchitecture and continues to release EVs 
and soluble factors under controlled laboratory conditions. Here, 
we report on such a system. Using nanotechnology, we analyzed 
individual EVs released by placental tissues ex vivo and assessed 
EV- bound and EV- encapsulated cytokines. Establishment and 
benchmarking this placental ex vivo system provides a basis to 
study the nature of various placental disorders and, in particular, the 
release of EVs and cytokines. Their release by the syncytiotropho-
blast into the maternal circulation has been proposed as a placental 
liquid biopsy, which can provide insight into the functional status of 
the organ and may be a source of biomarkers to predict pregnancy 
complications.146 Herein, we report a system of ex vivo placental 
villous and amnion tissues that can be used as an adequate model to 
study physiological and pathological processes during normal and 
complicated pregnancies.
2  | METHODS
2.1 | Sample preparation and storage
Placental tissues (the placenta and fetal membranes) from women 
who delivered at term without labor (n = 10) were obtained at 
the Detroit Medical Center, Wayne State University, and the 
Perinatology Research Branch, an intramural program of the Eunice 
Kennedy Shriver National Institute of Child Health and Human 
Development, National Institutes of Health, US Department of 
Health and Human Services (NICHD/NIH/DHHS) (Detroit, MI, 
USA).	 The	 collection	 and	 utilization	 of	 biological	materials	 for	 re-
search purposes were approved by the Institutional Review Boards 
of	 these	 institutions.	 All	 participating	 women	 provided	 written	
informed consent. Immediately after delivery, three random sam-
ples from the placental villi were collected using a metal grid and 
the Random Position Generator DICE software (Perinatology 
Research	Branch,	Detroit,	MI,	USA).	The	amnion	was	gently	sepa-
rated from the chorion of the fetal membranes. Samples from the 
placental villi and amnion were placed in 50- mL tubes containing 
DMEM and shipped overnight to NIH on cold packs. Upon receipt, 
villi were sectioned into 2 mm × 6 mm strips, washed thoroughly in 
1× phosphate- buffered saline (PBS) and cultured on Gelfoam ab-
sorbable collagen sponges (Pfizer, New York, NY) at the air- liquid 
interface, as has been described for other tissues147 in 0.1- μm fil-
tered phenol red free DMEM supplemented with 5% characterized, 
charcoal stripped FBS, 50 μg/mL gentamicin, and 2.5 μg/mL ampho-
tericin	B	at	37°C,	5%	CO2. The amniotic membrane was sectioned 
into 3 × 3 mm pieces, washed thoroughly with PBS, and cultured in 
same medium. Equivalent masses were cultured in triplicate for each 
donor.	Tissues	collected	at	days	1,	7,	and	14	were	fixed	in	10%	for-
malin, sent for paraffin embedding, sectioning, and H&E staining. 
H&E sections were evaluated by perinatal and obstetric patholo-
gists at Wayne State University School of Medicine. Medium was 
collected	 and	 changed	 at	 days	 1,	 4,	 7,	 10,	 and	 14	 after	 initiation.	
Medium samples were centrifuged at 400×g for 5 minutes to re-
move	cells	and	frozen	at	−80°C.
2.2 | Preparation of EV fractions
Medium samples were split into multiple fractions. One aliquot was 
kept untreated, and another portion was treated with Exoquick TC 
(System	Biosciences,	Palo	Alto,	CA),	 according	 to	 the	manufactur-
er’s protocols. Briefly, ExoQuick TC was added to supernatants at 
a ratio of 100 μL of ExoQuick TC to 500 μL of sample and refriger-
ated	overnight	at	4°C.	ExoQuick/sample	mixtures	were	centrifuged	
at 1500 × g for 30 minutes to pellet EVs. Supernatant was collected 
and saved for cytokine measurement of EV- free supernatant. The 
pellet was centrifuged again at 1500 × g for 5 minutes, and all traces 
of fluid were removed resulting in an EV-enriched preparation. The 
pellet was resuspended in 1× PBS in the original volume, and cy-
tokines were measured on intact and lysed EVs.
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2.3 | Cytokine measurement
We previously developed an in- house multiplexed bead- based assay 
for measurement of the following cytokines/growth factors: IL- 1α, IL- 
1β, IL- 2, IL- 4, IL- 6, IL- 8, IL- 10, IL- 13, IL- 15, IL- 16, IL- 18, IL- 33, calgranu-
lin	 A	 (S100A8),	 calgranulin	 C	 (S100A12),	 C-	reactive	 protein	 (CRP),	
CXCL6 (granulocyte chemotactic protein 2), CXCL13 (B lympho-
cyte chemo- attractant), eotaxin (CCL11), granulocyte- macrophage 
colony- stimulating factor (GM- CSF), growth- regulated alpha 
(GRO- α or CXCL1), HMGB1 (high mobility group box 1), interferon- β 
(IFN- β), interferon- γ (IFN- γ), interferon- γ- induced protein (IP- 10 or 
CXCL10),	 interferon-	inducible	 T-	cell	 alpha	 chemo-	attractant	 (ITAC	
or CXCL11), lactoferrin, macrophage colony- stimulating factor (M- 
CSF), monocyte chemo- attractant protein- 1 (MCP- 1 or CCL2), mac-
rophage migration inhibitory factor (MIF), monokine induced by 
IFN- γ (MIG or CXCL9), macrophage inflammatory protein- 1α (MIP- 1α 
or CCL3), MIP- 1β (CCL4), MIP- 3α (CCL20), regulated on activation 
normally	 T-	cell	 expressed	 and	 secreted	 (RANTES	 or	CCL5),	 trans-
forming growth factor- β (TGF- β), tumour necrosis factor- α (TNF- α), 
and	 TNF-	related	 apoptosis	 inducing	 ligand	 (TRAIL),	 as	 previously	
described with minor modifications.148-150	 All	 antibody	 pairs	 and	
protein standards were purchased from R&D Systems (Minneapolis, 
MN) except those for IFN- β	 and	 lactoferrin	 (Abcam,	 Cambridge,	
MA).	 Additional	 in-	house	 assays	 were	 designed	 for	 the	 following	
growth, angiogenic and anti- angiogenic factors and hormones: ac-
tivin	A,	A	disintegrin	and	metalloproteinase	domain	12	(ADAM-	12),	
adiponectin, angiogenin, CD40L, epidermal growth factor (EGF), 
endoglin, fasL, fibronectin, galectin- 1, human chorionic gonadotro-
pin	 (hCG),	 intercellular	 adhesion	 molecule	 1	 (ICAM-	1),	 insulin-	like	
growth factor- binding protein 1 (IGFBP1), interleukin- 1 receptor 
antagonist	(IL-	1Ra),	 IL-	27,	 leptin,	matrix	metalloproteinase-	7	 (MMP-	
7),	MMP-	9,	pregnancy-	associated	plasma	protein-	A	(PAPP-	A),	pros-
taglandin E2 (PGE2), placental growth factor (PIGF), resistin, serpin 
E1, tissue factor pathway inhibitor (TFPI), transforming growth 
factor beta 3 (TGF- β3), tyrosine- protein kinase receptor Tie- 2, tis-
sue inhibitor of matrix metalloproteinases 1 (TIMP- 1), tissue factor, 
Toll- like receptor 2 (TLR2), triggering receptor expressed on myeloid 
cells	1	(TREM-	1),	urokinase-	type	plasminogen	activator	(uPA),	uroki-
nase	 plasminogen	 activator	 receptor	 (uPAR),	 vascular	 endothelial	
growth factor (VEGF), vascular endothelial growth factor receptor 1 




natures (regions) were coupled to cytokine specific capture antibod-
ies, according to manufacturer’s recommendations, and stored at 
4°C.	All	antibody	pairs	were	verified	to	be	free	of	cross	reactivity.	
Standards and samples were combined with bead mixtures and in-
cubated	overnight	at	4°C.	Intact	EV	samples	and	lysed	EV	samples,	
to which Triton X was added at a final concentration of 1%, were run 
in separate wells. Plates were washed two times and incubated with 
mixtures of polyclonal biotinylated anticytokine antibodies for one 
hour at room temperature. Plates were washed twice and incubated 
for 25 minutes with 16 μg/mL streptavidin- phycoerythrin in PBS. 
Plates were washed twice, and beads were resuspended in PBS and 
read on a Luminex 200 analyzer with acquisition of 100 beads for 
each region and analyzed using Bioplex Manager software (BioRad, 
Hercules,	CA).	Cytokine	concentrations	were	determined	using	5P	
regression algorithms.
2.4 | EV labeling and capture
Extracellular vesicles were captured from culture supernatants 
via magnetic nanoparticles (MNPs) (Ocean NanoTech, San Diego, 
CA).	MNPs	were	coupled	to	anti-	PLAP	(clone	8B6,	Thermo	Fisher,	
Waltham,	MA	 and	 clone	 H17E2,	 BioRad),	 anti-	CD90	 (clone	 5E10,	
Biolegend,	San	Diego,	CA),	anti-	CD9	(clone	H19a,	Biolegend),	anti-
	CD63	 (H5C6,	 Biolegend),	 anti-	HLA-	ABC	 (W6/32,	 Biolegend),	 or	
mouse	 IgG	 (SouthernBiotech,	 Birmingham,	 AL)	 antibodies,	 per	
manufacturer’s protocol and as previously described.151 Briefly, 
200 μL of 15 nm MNPs are activated and then coupled with 1 mg 
antibody overnight. Coupled MNPs were washed twice on a mag-
net then resuspended in 2 mL of wash/storage buffer and stored at 
4°C.	EVs	 in	100	μL of culture supernatant were labeled with 1 μM 
BODIPY- FL maleimide [BODIPY™ FL N- (2- aminoethyl) maleimide, 
Thermo Fisher] for 15 minutes at RT and then captured with 20 μL 
of MNPs. MNPs were added in huge excess to EVs, and the ratio of 
MNPs to EVs was optimized to allow good capture efficiency and 
single particle detection, as previously described.151 Fluorescent 
detection antibodies were added for 30 minutes at room tempera-
ture. Detection antibodies for placental villous cultures included 









(Biolegend). Control staining was also performed with mouse anti- 
human	CD31,	CD41,	and	CD45	APC/Cy7	(Biolegend).	The	captured	
and stained complexes were separated from unbound EVs and an-
tibodies using MS magnetic columns (Miltenyi Biotec) in a magnetic 
field	using	OctoMACS	magnet	(Miltenyi	Biotec),	washed	four	times	
with 500 μL of PBS, and eluted from the column outside the magnet 
with 200 μL PBS and fixed with 1.5% paraformaldehyde. 123count 
ebeads (Thermo Fisher) were added to tubes for EV quantification. 
All	antibodies	were	tested	on	EV/MNP	complexes	singly	and	in	com-
bination to verify that antibodies bound with the same efficiency 
and that spectral overlap could be compensated.
2.5 | EV flow cytometry analysis
Purified complexes were acquired at low speed on an LSRII (BD 
Biosciences)	 flow	 cytometer	 equipped	 with	 355-	,	 407-	,	 488-	,	
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532- , and 638- nm lasers by triggering on BODIPY- FL fluores-
cence to acquire only labeled EVs. Fluorescence minus one 
stainings and isotype controls were used for setting gates, com-
pensations, and determining background staining. Megamix SSC 
beads	(BioCytex,	Parsippany,	NJ)	were	used	to	set	parameters	for	
estimated EV size; in general, EV size is overestimated due to the 
binding of MNPs to the EVs. Data were acquired with Diva 6.3 
and	analyzed	with	FlowJo	software	v10.4.1	 (Treestar	Software,	
Ashland,	OR).
2.6 | Measurement of EV- associated cytokines
Extracellular vesicles were captured as above using MNPs cou-
pled	 to	 mouse	 anti-	human	 antibodies	 to	 PLAP	 (8B6,	 Thermo	
Fisher), CD31 (WM59, Biolegend), CD90 (5E10, Biolegend), or 
HLA-	G	 (87G,	 Biolegend)	 antibodies.	 20	μL of MNPs were incu-
bated with 100 μL	of	culture	supernatants	overnight	at	4°C	and	
purified using MS magnetic columns as above. EV/MNP com-
plexes were eluted off columns, resuspended in their original 
volume, split in two, and analyzed by multiplexed bead assays on 
intact fractions and lysed (1% Triton X) fractions. Total EVs from 
culture supernatants were collected using ExoQuick TC as above 
and analyzed the same way.
2.7 | Statistical analysis
We	conducted	statistical	analysis	using	JMP10	(SAS	Institute,	Cary,	
NC). Results are represented as means ± standard error of the 
mean (SEM). The statistical differences were evaluated with paired 
Student’s t	test.	All	hypothesis	tests	were	two-	tailed	and	a	P value of 
≤.05	defined	statistical	significance.
3  | RESULTS
3.1 | Ex vivo tissue viability and function
3.1.1 | Histology
Samples of the villus tree and amnion were dissected and cultured as 
described in the Methods section. Tissue samples were collected at 
days	1,	7,	and	14	of	culture,	fixed,	paraffin-	embedded,	sectioned,	and	
H&E	stained	 (Figure	1).	At	 the	start	of	culture,	chorionic	villi	were	
viable and maintained normal morphology with well- preserved syn-
cytiotrophoblasts, intact blood vessels, and a lack of karyorrhexis; 
amnion	tissue	was	well	preserved.	At	day	7,	much	of	the	syncytio-
trophoblast appeared viable and well preserved, with focal areas of 
early degenerative changes in the form of karyorrhectic debris in 
F IGURE  1 Placental villous and amnion tissue explants maintain their cytoarchitecture. H&E sections of placental villous explants 
at	days	1	(A),	7	(B),	and	14	(C)	of	culture	(one	representative	tissue	of	10).	Villi	maintained	normal	morphology	with	well-	preserved	
syncytiotrophoblasts	and	blood	vessels	with	some	focal	degenerative	changes.	H&E	sections	of	amnion	explants	at	days	1	(D),	7	(E),	and	14	
(F) 14 of culture also show well- preserved tissue with focal degenerative changes at day 14
(A) (B) (C)
(E) (F)(D)
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blood vessels and villous stromal- vascular karyorrhexis. Most of the 
amnion	appeared	well	preserved	and	viable	at	day	7.	By	day	14,	pla-
cental villous tissue showed slightly more pronounced karyorrhexis 
and	degeneration	of	syncytiotrophoblast	than	at	day	7.	Amnion	tis-
sue at day 14 also showed mild degenerative changes in the form of 
pyknosis.
3.1.2 | Cytokine production
The release of cytokines by villi and amnion cultures over the en-
tire culture period was determined using in- house designed multi-
plexed bead- based assays.150 These assays revealed that cytokines 
are steadily produced in both placental villous and amnion cultures 
(Figure	2A,C).	 Villous	 tissue	 produced	 large	 amounts	 of	 the	 pro-	
inflammatory cytokines IL- 6, IL- 8, GRO- α, IP- 10, and MCP- 1, as well 
as	CRP	and	TRAIL	 (Figure	2A).	Cultures	also	released	considerable	
amounts	of	the	alarmins	calgranulin	A,	calgranulin	C,	and	HMGB1,	
and the antibacterial protein lactoferrin. IL- 13, IL- 16, and IL- 33 were 
also	 released,	 as	well	 as	 the	 chemokines	 ITAC,	MIF,	MIG,	MIP-	1α, 
MIP- 1β, MIP- 3α,	 and	RANTES.	Other	 cytokines	were	produced	 in	
smaller quantities (see Table S1).
Amnion	explants,	similar	to	villi	explants,	produced	cytokines	con-
stantly	over	the	duration	of	the	culture	period	(Figure	2C).	Amnion	and	
villous explants also produced large amounts of the pro- inflammatory 
cytokines IL- 6, IL- 8, GRO- α, IP- 10, and MCP- 1 as well as CRP and 
TRAIL.	 Such	 explants	 also	 produced	 the	 antimicrobial	 proteins	 cal-
granulin	C	and	lactoferrin	as	well	as	smaller	amounts	of	calgranulin	A.	
Moreover, the explants produced the prototypic alarmin HMGB1 as 
well as IL- 10, IL- 13, IL- 16, IL- 33, MIP- 1α, MIP- 1β, MIP- 3α, MIF, CXCL6, 
and	smaller	amounts	of	ITAC,	RANTES,	and	CXCL9	(see	Table	S1).
3.1.3 | Production of growth factors, and 
angiogenic and anti- angiogenic factors
The release of other growth factors, angiogenic factors, anti- 
angiogenic factors, and hormones was determined by multiplexed 
bead assays. Both villi and amnion explants also continuously 
produced these factors over the duration of the culture period 
(Figure	2B,D).	Villi	 explants	produced	 large	amounts	of	ADAM-	12,	
adiponectin,	 angiogenin,	 fibronectin,	 galectin-	1,	 ICAM-	1,	 IGFBP1,	
IL-	1Ra,	IL-	27,	PAPP-	A,	serpin	E1,	TFPI,	TIMP-	1,	uPA,	uPAR,	VEGFR1,	
and	VEGFR2,	as	well	as	hCG	and	PGE2	(Figure	2B).	A	complete	list	of	
factors produced is available in Table S2.
Amnion	explants	produced	large	amounts	of	many	of	the	same	
growth and angiogenic factors as villi explants including adiponectin, 
angiogenin,	fibronectin,	galectin-	1,	IGFBP1,	IL-	1Ra,	IL-	27,	serpin	E1,	
F IGURE  2 Placental villous and amnion tissue explants maintain cytokine and growth factor production throughout the culture period. 
Soluble cytokines, growth factors, and angiogenic and anti- angiogenic factors are produced by explants over the entire 14- day culture 
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TFPI,	TIMP-	1,	VEGFR1,	uPA,	and	uPAR,	and	the	hormones	hCG	and	
PGE2 (Figure 2D; See Table S2 for complete list).
3.2 | Analysis of placental villous EVs
To analyze EVs specifically from syncytiotrophoblasts (STB) of the 
explants,	magnetic	nanoparticles	 (MNPs)	coupled	to	anti-	PLAP	an-
tibody, an antigen specific to STB,123,152-155 were used. EVs were 
labeled	with	 BODIPY-	FL	 as	 described	 in	Methods.	Among	 several	
commercially	available	anti-	PLAP	antibodies,	we	selected	one	(clone	
8B6) that after its coupling to MNPs was specific in capture of STB- 
generated EVs and captured EVs most efficiently. We analyzed the 
STB- generated EVs for other antigens that have been described on 
STBs or STB EVs.
3.2.1 | Selection of PLAP antibodies for capture of 
syncytiotrophoblast EVs
We	 coupled	 two	 clones	 of	 PLAP	 antibodies	 to	MNPs	 and	 cap-
tured EVs from placental villous culture supernatants. MNPs cou-
pled	to	two	PLAP	clones	captured	similar	amounts	of	EVs:	With	
MNPs	coupled	to	clone	H17E2,	we	captured	108.8%	±	11.6%	of	
EVs captured with MNPs coupled to clone 8B6. However, MNPs 
coupled	to	clone	H17E2	captured	3.3	±	0.3	(n	=	3)	times	more	of	
non-	specific	 EVs,	 expressing	HLA-	ABC.	 Therefore,	 we	 selected	
clone 8B6 for future experiments since MNPs coupled to the 
antibodies of this clone seemed to be more specific to capture 
PLAP-	positive	EVs.
3.2.2 | Specificity of EV capture
We	 further	 verified	 the	 specificity	 of	 our	 anti-	PLAP-	MNPs	 by	
incubation with amnion explant supernatants which should 
not	 contain	 PLAP+ EVs156 and found they captured on average 
4.7%	±	0.5%	of	total	EVs	(n	=	3).	That	was	not	different	from	the	
amount captured with control mouse IgG isotype MNPs: With 
these MNPs, we captured from the placental villous tissue super-
natants 4.8% ± 1.1% of EVs that were captured by specific anti- 
PLAP-	MNPs	(n	=	3).
3.2.3 | The lack of non- STB antigens on anti- PLAP–
captured STB- generated EVs
To	 further	 confirm	 specificity	of	 the	PLAP-	captured	EVs,	we	 cap-
tured EVs from villous samples pooled from multiple donors and 
stained	for	CD31,	CD41,	CD45,	and	HLA-	ABC,	all	of	which	should	
be absent on STB EVs.156-158	All	 antibodies	were	 labeled	with	 the	
same fluorophore and collected into a single “dump” gate. We found 
that they were present on only 1.6% ± 0.5% of captured EVs (n = 3). 
For	the	remaining	experiments,	we	included	only	HLA-	ABC	and	used	
the lack of this marker as an additional criterion for STB EVs. Single 
staining	for	HLA-	ABC	on	EVs	captured	by	anti-	PLAP-	MNPs	revealed	
0.7%	±	0.3%	of	total	EVs	(n	=	3).
3.2.4 | Syncytiotrophoblast markers on PLAP- 
positive EVs
Next, we evaluated the distribution of several “phenotypic” mark-
ers	on	the	EVs	captured	by	MNPs	through	PLAP.	We	chose	mark-
ers which have been previously described in the literature as being 
surface markers either of STB themselves or of the STB- generated 
EVs,154,159-162	 namely	 CD51,	 CD63,	 CD105,	 CD200,	 CD274,	 and	
syncytin- 1. Culture supernatants were stained with BODIPY- FL to 
label	 EVs	 and	 then	 captured	with	 anti-	PLAP-	MNPs,	 and	 stained	
with antibodies to the above- listed markers (as well as with an-
tibodies	 to	 HLA-	ABC).	 The	 MNP/labeled	 EV	 complexes	 were	
washed on magnetic columns, eluted, and acquired on a flow cy-
tometer	set	to	threshold	on	the	BODIPY-	FL	EV	 label.	HLA-	ABC+ 
EVs were excluded from the analysis and the rest quantified by 
expression of the markers and approximate size (See Figure S1 for 
gating strategy).
Flow cytometry analysis revealed that CD200 had the high-
est	 expression	 on	 PLAP-	MNPs–captured	 EVs,	 being	 present	 on	
67.3%	±	3.1%	of	vesicles	at	day	1,	and	syncytin-	1	was	the	lowest	
at	1.7%	±	0.2%.	The	other	markers	were	expressed	on	24%-	34%	
of	 vesicles	 (Figure	3A).	 EV	 size	 was	 estimated	 using	 Megamix	
SSC beads. The vesicles formed a continuum rather than dis-
creet populations, but small vesicles of the size 200 nm or less 
were the most plentiful and over 500 nm the least common 
(Figure 3B).
The distribution of the markers varied with vesicles of dif-
ferent sizes (Figure 3C- H). Only CD200 was highly expressed 
(58.8% ± 4.4%) at day 1 on small vesicles (of the size of 200 nm or 
less), while all other markers were present at lower levels on these 
small vesicles (0.5%- 18.4%). Levels of CD51, CD63, CD105, and 
CD274	were	highest	on	vesicles	of	the	size	of	250-	500	nm,	and	syn-
cytin- 1 was highest on vesicles of the size above 500 nm.
We analyzed co- expression of markers on individual vesicles 
and	 found	 CD51,	 CD63,	 CD105,	 and	 CD274	 were	 most	 often	
co- expressed with CD200, the most highly expressed marker on 
the placental villous EVs (Figure S2). Syncytin- 1 was the least co- 
expressed molecule, but was most often co- expressed with CD105.
Assessment	 of	 PLAP-	captured	 vesicles	 over	 time	 showed	
that the total number of vesicles decreased throughout the cul-
ture period. Total EVs at day 1 were 1.91 ± 3.3 × 106 EVs/mL 
and	 declined	 to	 9.4	±	1.7	×	104 EVs/mL by day 14 (see Table S3 
for EV counts). The distribution of EVs in different size ranges 
shifted slightly over time (Figure 3B). The amount of small vesicles 
(≤200	nm)	decreased	over	time,	starting	at	52.1%	±	3.0%	at	day	1	
and dropping to 25.5% ± 3.6% at day 14, whereas vesicles of all 
other size ranges increased slightly in percentage with length of 
culture.
The	amount	of	PLAP-	captured	vesicles	expressing	each	marker	
was	 similar	 at	 days	1	 and	4,	 but	 decreased	 slightly	 by	 day	7	 and	
further by day 14, except for syncytin- 1 expressing EVs, which 
increased in over time (Figure 3C- H). Except for syncytin- 1, all 
markers maintained over time a similar distribution between EVs of 
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different size. The percentage of EVs double positive for markers 
was stable up to day 14, except EVs double positive for syncytin- 1 
and	all	other	markers	that	increased	slightly	over	time	(Figure	S2A).
These results demonstrate that placental villous explants 
produce EVs carrying typical STB markers throughout the cul-
ture period. EVs expressing each marker maintained a similar 
F IGURE  3 Placental villous tissues release a variety of EVs carrying different surface markers. Placental villous explants release EVs that 
(A)	carry	surface	markers	that	are	representative	of	syncytiotrophoblast	cells	throughout	culture	and	(B)	are	of	a	variety	of	sizes	(average	
%	of	total	EVs	for	each	time	point	±	SEM,	n	=	10).	EVs	carrying	(C)	CD51,	(D)	CD63,	(E)	CD105,	(F)	CD200,	(G)	CD274,	and	(H)	syncytin-	1	
maintain similar patterns of expression over time and some are preferentially expressed on EVs of certain sizes (average % of total EVs for 
each size range. Mean ± SEM, n = 10)
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size distribution over time, but the overall percentage of vesi-
cles carrying most of these markers decreased at later days of 
culture.
3.3 | Analysis of amnion EVs
In parallel to the analysis of the STB- released EVs, we analyzed the 
EVs released by amnion explants by identification of specific cel-
lular antigens on these EVs. EVs were labeled with BODIPY- FL as 
described in Methods. The main cells of interest in amnion explants 
were	amnion	epithelial	cells	(AECs;	as	they	are	in	contact	with	amni-
otic fluid, thus likely to be involved in fetal communication), as well 
as	the	underlying	amnion	mesenchymal	stem	cells	(AMSCs).	We	used	
MNPs coupled to antibodies specific to antigens that these cells 
carry.	As	CD90	is	a	marker	expressed	by	both	AECs	and	AMSCs,163 
we investigated this protein as a target for capture with MNPs using 
anti- CD90 antibodies.
3.3.1 | Optimizing capture of amnion EVs
We incubated amnion explant culture supernatants with anti- CD90 




CD90 is the most exclusive marker for our cells of interest, we used 
anti- CD90 MNPs for our further experiments.
3.3.2 | Specificity of EV capture
Next, we verified whether anti- CD90 MNPs specifically capture 
only	EVs	carrying	CD90.	As	a	negative	control,	we	used	these	MNPs	
to capture EVs from placental villous culture supernatants (which 
should release very few EVs carrying CD90, potentially from placen-
tal MSCs164). We found that these MNPs captured on average only 
2.5% ± 0.8% of total EVs (n = 3). We also confirmed MNP specificity 
by incubating amnion tissue supernatants with mouse IgG isotype 
MNPs, which captured 6.3% ± 1.4% of EVs compared to anti- CD90 
MNPs (n = 3).
3.3.3 | Lack of irrelevant antigens on AEC- generated 
EVs
We captured EVs from amnion samples from multiple donors 




vealed that these markers were present on only 4.8% ± 0.5% of 
captured EVs. Further analysis of amnion EVs included only anti-
bodies	 against	HLA-	DR,	which	 contributed	 2.8%	±	0.3%	of	 total	
EVs (n = 3), and this population was excluded from flow cytometry 
analysis.
3.3.4 | AEC and AMSC markers are revealed on 
amnion explant EVs
The distribution on EVs of several “phenotypic” markers expressed 
by	 AECs	 or	 AMSCs,166,167 namely CD29, CD44, CD105, CD140b, 
CD324, and CD326, were determined. EVs were labeled with 
BODIPY- FL, captured with anti- CD90 MNPs, and stained with an-
tibodies	to	the	above	markers	(in	addition	to	HLA-	DR).	The	labeled	
EV- MNP complexes were washed on magnetic columns, eluted, 
and then acquired on a flow cytometer set to threshold on the 
BODIPY-	FL	label.	Any	vesicles	positive	for	HLA-	DR	were	excluded	
and the remainder quantified by size, estimated by Megamix SSC 
beads, and expression of the markers of interest (see Figure S1 for 
gating strategy).
First, we evaluated EVs from amnion culture supernatants at 
day	1	of	culture	(Figure	4A).	We	found	that	CD105	was	the	most	
highly	expressed	marker	being	present	on	18.5%	±	0.7%	of	all	cap-
tured EVs, and CD140b was the least expressed on 4.0% ± 0.6% 
of EVs (n = 10). CD44, CD326, CD324, and CD29 were on ap-
proximately on 15%, 12%, 10%, and 9% of EVs, respectively. EVs 
were equally distributed among most size ranges, except EVs of 
200 nm or less which were expressed on 4.6% ± 0.6% of all EVs 
(Figure 4B). Most markers were more likely to be on larger vesi-
cles (Figure 4C- H). CD105 was highest on vesicles of the size of 
500 nm and over, CD140b was much higher on vesicles with the 
size over 500 nm, and CD44, CD324, CD326, and CD29 were dis-
tributed more evenly between all size ranges except the smallest.
Evaluation of marker co- expression demonstrated that CD29 
and	CD44	were	the	most	commonly	found	together	(4.2%	±	0.7%	of	
EVs	at	day	1),	followed	by	CD140b	and	CD326	(3.1%	±	0.7%	EVs	at	
day 1; Figure S2B).
Next, we investigated how the number of CD90- captured ves-
icles	changed	over	time.	Unlike	PLAP-	captured	EVs	from	placental	
villous explants, the amount of amnion- generated vesicles captured 
with CD90- MNPs did not decrease over time. The total concentra-
tion of vesicles at day 1 was 9.5 ± 1.4 × 104/mL and at day 14 was 
9.9 ± 1.8 × 104/mL (see Table S3 for all EV counts). The amount of 
amnion EVs remained constant over the entire culture period in all 
aspects: in size ranges of vesicles (Figure 4B), in the fractions of total 
EVs for each (Figure 4C- H), and for the fractions of double positive 
EVs (Figure S2B).
These results confirm that amnion explants continually produce 
EVs	representative	of	AECs	and	AMSCs	over	14	days	of	culture.
3.4 | Analysis of EV- associated cytokines
3.4.1 | EVs from different cells carry 
different cytokines
We captured EVs from culture supernatants at day 4 with MNPs 
coupled with specific capture antibodies to investigate whether EVs 
with different surface markers (ie, generated by different cells) carry 
different cytokines.
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3.4.2 | Placental villous EVs
Total EVs were isolated from placental villous culture supernatants 
using Exoquick TC™. From this isolate, we captured several types 
of	 EVs	 using	 anti-	PLAP-	coupled	MNPs	 to	 capture	 STB-	generated	
EVs, anti- CD31 MNPs to capture EVs generated by endothelial 
cells,	and	HLA-	G	to	capture	EVs	released	by	cytotrophoblasts	and	
placental MSCs. Following MNP capture, EVs were magnetically 
isolated as described in Methods, and the EV- associated cytokines 
and growth factors were evaluated. Surface- associated proteins 
were measured directly with multiplexed bead assays, and total EV 
proteins were measured after EVs were lysed. We then subtracted 
the surface quantity from the total to determine the internal protein 
concentrations.
F IGURE  4 Amnion	tissues	release	a	variety	of	EVs	carrying	different	surface	markers.	Amnion	explants	release	EVs	that	(A)	carry	
numerous surface markers that are representative of amnion epithelial and mesenchymal cells throughout culture and (B) are of a variety of 
sizes (average % of total EVs for each time point ± SEM, n = 10). EVs carrying (C) CD29, (D) CD44, (E) CD105, (F) CD140b, (G) CD324, and (H) 
CD326 maintain similar patterns of expression over time and some are preferentially expressed on EVs of certain sizes (average % of total 
EVs for each size range. Mean ± SEM, n = 10)
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Multiple cytokines were found associated with EVs, and those 
in the greatest amounts were IL- 4, IL- 8, IL- 10, IL- 13, IL- 33, calgran-
ulin C, CRP, IFN- γ, IP- 10, MIF, MIG, MIP- 3α,	and	TRAIL.	(See	Table	
S4 for EV cytokine concentrations). Overall, cytokines tended to be 
EV-	encapsulated	 rather	 than	 on	 their	 surface	 (Figure	5).	 HLA-	G–
captured EV had slightly more cytokines on their surface compared 
to	anti-	PLAP–	or	anti-	CD31–captured	EVs.	PLAP-	captured	EVs	car-
ried significantly more IL- 4, IL- 16, MIG, and TGF- β compared to both 
other types of capture (P < .05, n = 5), and were located predomi-
nantly inside EVs (Figure 5B). CD31- captured EVs were significantly 
higher in MIP3α	and	CXCL6	compared	to	HLA-	G–captured	EVs	only	
(P	<	.05,	 n	=	5),	 and	 these	were	 encapsulated	 (Figure	5C).	HLA-	G–
captured EVs were higher than both other captures in GM- CSF, IP- 
10, and MIF (P < .05, n = 5), and these were both on the surface and 
encapsulated (Figure 5D).
3.4.3 | Amnion EVs
Total EVs were isolated from amnionic culture supernatants using 
Exoquick	TC™.	Amnion	EVs	were	captured	with	anti-	CD90	MNPs,	
to	 capture	 presumably	 EVs	 from	 both	 AECs	 and	 AMSCs,	 and	
HLA-	G	 antibodies	 to	 capture	EVs	 from	 selected	 cells,	 as	HLA-	G	
has	been	reported	 in	various	 levels	on	AECs	and	only	weakly	on	
AMSCs.	Also,	many	cytokines	were	associated	with	EV	(see	Table	
S5) especially IL- 4, IL- 8, IL- 10, IL- 13, IL- 33, calgranulin C, GRO- 
α, IFN- γ, MIF, MIG, MIP- 3α,	 and	TRAIL.	Similar	 to	EVs	 from	pla-
cental villous explants, for amnion explant EVs, most cytokines 
were	 predominantly	 inside	 EVs	 (Figure	6).	 HLA-	G–captured	 EVs	
expressed slightly more cytokines on their surface compared to 
CD90- captured EVs (Figure 6B,C). CD90 MNP- captured EVs had 
significantly higher amounts of IL- 4, IL- 10, IL- 13, IL- 33, CXCL6, eo-
taxin,	 ITAC,	MIG,	MIP3α, and TGF- β	 than	HLA-	G–captured	 EVs	
(P < .05, n = 5) and most were predominantly inside (Figure 6B). 
HLA-	G	captured	the	highest	levels	of	calgranulin	C,	GM-	CSF,	MIF,	
and MIP- 1β compared to CD90- captured EVs (P < .05, n = 5), and 
most were internal to the EVs (Figure 6C).
3.4.4 | EVs from different cells carry different 
growth factors
Extracellular vesicles from placental villous tissue also contained 




well as hCG and PGE2. Similar to cytokines, these growth factors 
F IGURE  5 Distribution of cytokines between the surface and inner volume of EVs from placental villous tissues. Distribution between 
encapsulated	and	surface	cytokines	is	shown	for	placental	villous	cultures.	(A)	Total	EVs	isolated	by	Exoquick™;	(B)	anti-	PLAP-	MNP–
captured	EVs;	(C)	anti-	CD31	MNP–captured	EVs;	(D)	anti-	HLA-	G	MNP–captured	EVs.	Free	and	EV-	associated	cytokines	are	expressed	as	
percent of total (mean ± SEM, n = 5). Blue bars: surface- associated cytokines, red: EV- encapsulated. Multiplexed bead assay measurements 
on samples collected at day 4 (cumulative amount for days 1- 4 of culture)
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were predominantly encapsulated within EVs rather than on their 
surface	(Figure	7),	although	HLA-	G–captured	EVs	had	more	surface-	
associated	 than	 the	 other	 two	 captures.	 PLAP-	captured	 EVs	 had	
significantly	 higher	 amounts	 of	 EV-	associated	ADAM12,	 endoglin,	
and	PIGF	than	either	CD31-	or	HLA-	G–captured	EVs	(P < .05, n = 5). 
PIGF	 was	 mostly	 on	 the	 surface	 of	 EVs,	 whereas	 ADAM12	 and	
endoglin	 were	 predominantly	 encapsulated	 (Figure	7B-	D).	 CD31-	
captured	EVs	carried	significantly	higher	amounts	of	 internal	 IL-	27	
and	TREM-	1	than	HLA-	G	EVs	(P	<	.05,	n	=	5).	HLA-	G–captured	EVs	
contained significantly more adiponectin, CD40L, EGF, FasL, fi-
bronectin, galectin- 1, PGE2, resistin, TFPI, TGF- β3, Tie- 2, tissue fac-
tor,	TREM-	1,	uPA,	uPAR,	VEGFR1,	and	VEGFR2	than	both	PLAP-	and	
CD31- captured EVs (P < .05, n = 5).
Growth and angiogenic factors were also associated with amnion 
EVs	 (see	 Table	 S7);	 and	 activin	 A,	 adiponectin,	 fibronectin,	 galec-
tin-	1,	 ICAM-	1,	 IL-	1Ra,	 PAPP-	A,	 serpin	 E1,	 TFPI,	 TIMP-	1,	 TREM-	1,	
uPA,	uPAR,	and	VEGFR1,	as	well	as	hCG	and	PGE2,	were	secreted	in	
the	highest	amounts.	Amnion	EVs	also	carried	most	growth	factors	
predominantly	 inside	 EVs,	 and	 HLA-	G–captured	 EVs	 had	 slightly	
more surface growth factors than CD90 captured (Figure 8). CD90 
MNPs-	captured	 EVs	 had	 significantly	 higher	 amounts	 of	 PAPP-	A,	
and TREM- 1 (P	<	.05,	n	=	5),	with	PAPP-	A	being	predominantly	 in-
side and TREM- 1 being both on the surface and inside (Figure 8B). 
HLA-	G	captured	significantly	higher	 levels	of	adiponectin,	CD40L,	
EGF,	endoglin,	FasL,	galectin-	1,	ICAM-	1,	IGFBP1,	IL-	1Ra,	PGE2,	re-




4.1 | Previous studies of placental explants
Several techniques for maintaining placental explants have been 
described,168-171 with different models being useful for different 
purposes. Typically, placental tissues are immersed in the culture 
medium either free floating or supported by Matrigel™ or Millicell 
inserts. In these experiments, tissues remain viable up to 9 days 
and produce human chorionic gonadotropin (hCG) and placental 
lactogen.172 Most of these models report that STBs are lost in the 
first 1- 2 days of culture, but some regeneration was observed by 
5-	7	days.173,174
Following the pioneer works of Hoffman et al,175,176 we devel-
oped cultures of ex vivo tissues maintained on collagen sponges at 
the medium/air interface to study HIV pathogenesis in human lym-
phoid,177-181 cervico- vaginal,182-184 and recto- sigmoid tissues,185 and 
to investigate the physiology of atherosclerotic plaques186,187 ex vivo. 
A	comparable	 culture	method	was	used	 to	 study	 cytomegalovirus	
F IGURE  6 Distribution of cytokines between the surface and inner volume of EVs from amnion tissues. Distribution between 
encapsulated	and	surface	cytokines	is	shown	for	amnion	cultures.	(A)	Total	EVs	isolated	by	Exoquick™;	(B)	anti-	CD90	MNP–captured	EVs;	
(C)	anti-	HLA-	G	MNP–captured	EVs.	Free	and	EV-	associated	cytokines	are	expressed	as	percent	of	total	(Mean	±	SEM,	n	=	5).	Blue	bars:	
surface- associated cytokines, red: EV- encapsulated. Multiplexed bead assay measurements on samples collected at day 4 (cumulative 
amount for days 1- 4 of culture)
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infection.188 Here, we apply a similar technique to study placental 
tissue secretion of EVs, cytokines, and growth factors ex vivo.
4.2 | The establishment of a three- dimensional 
culture to study extracellular vesicles and cytokines
The purpose of the present study was to develop a laboratory 
model to study soluble factors and EVs generated by placental vil-
lous tissue. This is important since both EVs and soluble factors, in 
particular placental cytokines,189,190 are implicated in maternal- fetal 
communication. This especially concerns STBs that are in direct con-
tact with the maternal blood, and amnion epithelial cells that sur-
round the amniotic cavity containing the fetus. Under our protocol, 
we found that explants of both placental villous tissue and amnion 
are viable for at least 14 days as evidenced by histological analysis. 
Both types of explants continue to secrete cytokines and growth 
factors over 14 days of culture’ providing further evidence of tissue 
viability and functionality.
Evaluating these secreted factors in tissue models allows the 
determination of tissue origin of these factors, which is not easily 
accomplished in vivo. Yet, we cannot rule out a minor contribution 
of factors derived from entrapped maternal or fetal cells in placental 
vessels.
A	number	of	publications	have	addressed	placental	EVs	and	their	
potential role in pregnancy and its complications.130,132,133,146,191-225 
Several ex vivo (eg, placental perfusion)214,226-232 and in vivo233-236 
systems have been used as a source of EVs. Placental perfusion is a 
useful method for obtaining large numbers of EVs directly from the 
placenta; however, this technique is suitable only for a short period 
of time (2- 6 hours) after delivery.237 In vivo studies on EVs obtained 
from maternal blood are difficult to interpret because of multiple po-
tential cellular sources of these EVs. Focusing on the analysis of EVs 
generated by placental cells requires the ability to trace particular 
EVs to their cells of origin. Toward this goal, rather than “bulk” anal-
ysis of EVs, we employed a newly developed nanotechnology plat-
form,238 which allows capture of EVs with magnetic nanoparticles 
(MNPs) coupled to specific antibodies against EV surface antigens 
and analysis of these EVs individually. The captured EVs can then 
be stained with additional antibodies to reveal specific antigens of 
interest. Here, we applied this analysis to EVs generated by placental 
explants.
4.3 | Analysis of placental villous 
extracellular vesicles
We found that STB- specific EVs can be captured from placen-
tal	 villous	 culture	 supernatants	 using	 anti-	PLAP-	MNPs.	 PLAP	 is	
a sialoglycoprotein enzyme present almost exclusively on STBs 
and has been used as a marker of STB- derived EVs.123,153,155 We 
first demonstrated specificity of capture by demonstrating that 
F IGURE  7 Distribution of growth factors between the surface and inner volume of EVs from placental villous tissues. Distribution 
between	encapsulated	and	surface	growth	factors	is	shown	for	placental	villous	cultures.	(A)	Total	EVs	isolated	by	Exoquick™;	(B)	anti-	
PLAP–MNP–captured	EVs;	(C)	anti-	CD31	MNP–captured	EVs;	(D)	anti-	HLA-	G	MNP–captured	EVs.	Free	and	EV-	associated	growth	factors	
are expressed as percent of total (mean ± SEM, n = 5). Blue bars: surface- associated growth factors, red: EV- encapsulated. Multiplexed bead 
assay measurements on samples collected at day 4 (cumulative amount for days 1- 4 of culture)
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anti-	PLAP-	MNPs	capture	 significant	 amounts	of	EVs	 from	placen-
tal villous explants but very few EVs from culture supernatants of 
amnion	explants.	PLAP-	captured	EVs	also	do	not	express	non-	STB	
markers	 including	 CD31,	 CD41,	 CD45,	 and	 HLA-	ABC	 above	 the	
background level (EVs captured by isotype control MNPs). EVs were 
expressed throughout the entire 14 days of culture, although their 
quantities declined at day 14.
We	assessed	the	PLAP-	captured	EVs	for	other	surface	proteins	
previously described to be expressed on STBs or on their EVs, CD51, 
CD63,	 CD105,	 CD200,	 CD274,	 and	 syncytin-	1.	 All	 these	 proteins	
were	 found	 albeit	 in	 various	 quantities	 on	 PLAP-	MNP–captured	
EVs.239 CD51, or vitronectin receptor alpha chain, is an adhesion 
molecule.239 CD63 is a tetraspanin known to associate with mem-
branes of intracellular vesicles.239 CD105, also known as endoglin, 
has a crucial role in the regulation of angiogenesis.240 CD200, also 
named OX- 2 membrane glycoprotein, may have a role in macro-
phage differentiation.241	 CD274	 or	 programmed	 death-	ligand	 1	
(PD- L1) is an immune checkpoint molecule that may have a role in 
immune suppression during pregnancy.242-244 Syncytin- 1 mediates 
trophoblast fusion and may have a role in tolerance to fetal anti-
gens.245,246 Herein, CD200 was the most widely expressed marker 
and syncytin- 1 the least expressed. These markers demonstrated 
some differences in their expression on EVs of different size ranges; 
for instance, most markers were expressed on only a small percent-
age of small EVs, except for CD200. These differences may reflect 
differential function of these EVs. Whatever these functions are, the 
overall pattern of these antigens expressed on the different sizes of 
EVs remained constant’ again demonstrating viability of the ex vivo 
tissues.	 Also,	 co-	expression	 of	 the	 various	 markers	 remains	 fairly	
constant over time.
4.4 | Analysis of extracellular vesicles produced 
by amnion
Extracellular vesicles were also produced by amnion and were cap-
tured with anti- CD90 MNPs. CD90, a cell surface glycoprotein in-
volved	in	cell	adhesion,	 is	expressed	on	both	AECs	and	AMSCs,	as	
well at varying levels on fibroblasts, neurons, and activated endothe-
lial cells.163,247-250 We confirmed specificity of capture by showing 
anti- CD90 MNPs captured very few EVs generated by placental 
villous	tissue.	Also,	CD90	MNP-	captured	EVs	 lacked	expression	of	
markers that should not be present on amnion- generated EVs, in-
cluding	CD31,	CD41,	CD45,	 and	HLA-	DR.	 EVs	were	 generated	 at	
constant levels throughout all the 14 days of culture and maintained 
the same size distributions. These EVs carried other proteins on their 
surface	that	have	previously	been	described	on	AECs	and	AMSCs.	
These included CD29, CD44, CD105, CD140b, CD324, and CD326, 
which are involved in cell- cell and cell- matrix interactions, cell adhe-
sion, and migration.251-253 CD29 (integrin beta- 1) acts as a fibronectin 
receptor.252 CD44 is a receptor for hyaluronic acid.254 CD140b is a 
tyrosine kinase receptor for members of the platelet-derived growth 
factor	family	and	a	marker	for	naive	AMSCs.255 CD324 or E- cadherin 
F IGURE  8 Distribution of growth factors between the surface and inner volume of EVs from amnion tissues. Distribution between 
encapsulated	and	surface	growth	factors	is	shown	for	amnion	cultures.	(A)	Total	EVs	isolated	by	Exoquick™;	(B)	anti-	CD90	MNP–captured	
EVs;	(C)	anti-	HLA-	G	MNP–captured	EVs.	Free	and	EV-	associated	growth	factors	are	expressed	as	percent	of	total	(mean	±	SEM,	n	=	5).	
Blue bars: surface- associated growth factors, red: EV- encapsulated. Multiplexed bead assay measurements on samples collected at day 4 
(cumulative amount for days 1- 4 of culture)
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is a regulator of epithelial junction formation.256 CD326, also known 
as	Ep-	CAM,	 is	an	epithelial	cell	 surface	antigen.253 Herein, CD105 
was the most widely expressed marker and CD140b was the least 
expressed on amnion- derived EVs. These markers demonstrated 
some differences in their expression on EVs of different size ranges, 
but all were least prevalent on the smallest vesicles. Overall, the pat-
tern of expression on the different sizes of EVs remained constant 
over time. Moreover, co- expression of the various markers remains 
fairly constant over time.
4.5 | Cytokines and other factors in EVs of 
different phenotypes
Here, we demonstrate that not only cytokines, but many other 
growth factors, and angiogenic and anti- angiogenic factors are as-
sociated with EVs from placental villous and amnion tissues. These 
factors can be on the EV surface or encapsulated within the vesicles. 
In this study, we took this analysis one step further from the analysis 
of association of these factors with general EVs to their association 
with EVs that carry particular membrane proteins. Specifically, we 
captured EVs using MNPs coupled to antibodies that select for cer-
tain EV populations, and analyzed the cytokine and growth factor 
content of these EV fractions.
We	found	 that	placental	villous	EVs	captured	via	PLAP,	CD31,	
and	HLA-	G	not	only	carry	different	levels	of	these	factors,	but	their	
distributions between the EV surface and internal space were dif-
ferent. Some cytokines segregated completely between different 
EVs.	For	example,	eotaxin	and	HMGB1	were	present	only	in	HLA-	G	
MNP–captured	 EVs,	 and	 ITAC	was	 observed	 exclusively	 in	 CD31	
MNP-	captured	 EVs.	 IL-	13,	 RANTES,	 and	 PGE2	 were	 not	 present	
in	CD31	EVs,	but	were	 found	 in	both	PLAP	and	HLA-	G–captured	
EVs,	whereas	hCG	was	absent	in	HLA-	G	EVs.	Some	cytokines	were	
carried exclusively on the EV surface, for example IL- 4, IL- 13, and 
eotaxin	 in	 HLA-	G	 MNP–captured	 EVs,	 whereas	 IL-	16,	 IL-	33	 and	
RANTES	were	exclusively	inside	HLA-	G	MNP–captured	EVs.	Other	
cytokines were found on the surface in EVs captured through one 
membrane protein, but internally in EVs captured through another 
protein. For example, IL- 4 and MIG were found internally in EVs cap-
tured	with	PLAP-	MNP	and	CD31	MNP,	but	on	the	surface	in	HLA-	G	
MNP- captured.
In amnion tissue, we specifically captured EVs using anti- CD90 
and	 anti-	HLA-	G	MNPs,	 analyzed	 their	 cytokine	 and	 growth	 fac-
tor content, and found differences in amounts and distributions of 





This complex differential distribution of cytokines between 
EVs of different origin and phenotype suggests a fine regulation 
of their biogenesis and indicates different biological functions of 
these EVs. To identify these functions EVs should be character-
ized individually rather than in bulk. The ability to characterize 
and distinguish individual EVs generated by different cell types 




may be co- expressed in placental villous tissue. This distinction 
may be the reflection of their differential biological role.
The use of the placental tissue culture described herein coupled 
with the newly described nanotechnology provides a novel and 
powerful tool for probing maternal- fetal communication through 
EVs that can be now traced to their cellular/tissue origin, charac-
terized by their surface- associated and encapsulated proteins. This 
multifactorial characterization of EVs in an ex vivo tissue system will 
enable us to narrow the search for possible placental biomarkers in 
maternal blood and amniotic fluid and identify their changes in var-
ious pathologies.
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